Latest news
Annexon: Early FORWARD Study GBS Data Reinforce First-in-Class C1q Opportunity; Buy Rating and $14 Price Target Reaffirmed - TipRanksTipRanks · Fri, 07 Aug 2026 10:33:21 GMTAnnexon announces tanruprubart data from FORWARD study - TipRanksTipRanks · Thu, 06 Aug 2026 22:02:22 GMTGoldman Sachs reiterates Neutral on Annexon stock after GBS data - Investing.comInvesting.com · Thu, 06 Aug 2026 21:07:00 GMTAnnexon reports initial FORWARD study results for tanruprubart in Guillain-Barré syndrome - Traders UnionTraders Union · Thu, 06 Aug 2026 19:10:22 GMTAnnexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients - BitgetBitget · Thu, 06 Aug 2026 19:02:10 GMTAnnexon Announces Positive Clinical Outcomes from GBS FORWARD Study on Tanruprubart - kalkinemedia.comkalkinemedia.com · Thu, 06 Aug 2026 17:44:27 GMTAnnexon, Inc. Reports Early Clinical Responses in First U.S. and European Patient Cohort of GBS FORWARD Study with Tanruprubart - marketscreener.commarketscreener.com · Thu, 06 Aug 2026 15:47:18 GMTAnnexon Highlights Promising Early FORWARD GBS Study Results - TipRanksTipRanks · Thu, 06 Aug 2026 13:13:24 GMT